| Assessment Status |
Rapid Review Complete |
| HTA ID |
26031 |
| Drug |
Toripalimab for metastatic oesophageal squamous cell carcinoma |
| Brand |
Loqtorzi® |
| Indication |
Toripalimab (Loqtorzi®) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. |
| Rapid review commissioned |
30/06/2026 |
| Rapid review completed |
22/07/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of toripalimab (Loqtorzi®) for this indication compared with the current standard of care. |
